Manneh Kopp et al21 reported no significant correlation between the clinical outcome in patients with recurrent GBM treated with Bev and histopathological parameters such as the Ki‐67 labeling index, various molecules including c‐Met, HIF‐1, and VEGFA, and neuroradiological parameters. This evidence concerns the gene VEGFA and glioblastoma.